(Q40047898)

16 September 2017

Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo (English)

1 reference

16 September 2017

1 reference

1 reference

J I Johnsen

1

1 reference

16 September 2017

L Segerström

2

1 reference

16 September 2017

A Orrego

3

1 reference

16 September 2017

L Elfman

4

1 reference

16 September 2017

M Henriksson

5

1 reference

16 September 2017

B Kågedal

6

1 reference

16 September 2017

S Eksborg

7

1 reference

16 September 2017

B Sveinbjörnsson

8

1 reference

16 September 2017

P Kogner

9

1 reference

16 September 2017

language of work or name

English

0 references

publication date

19 November 2007

1 reference

16 September 2017

1 reference

16 September 2017

27

1 reference

16 September 2017

2910-2922

1 reference

16 September 2017

20

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.onc.1210938

16 September 2017

0 references

cites work

Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210938

7 January 2021

Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210938

7 January 2021

Neuroblastoma: biological insights into a clinical enigma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210938

7 January 2021

Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210938

7 January 2021

Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210938

7 January 2021

Gene therapy-mediated expression by tumor cells of the angiogenesis inhibitor flk-1 results in inhibition of neuroblastoma growth in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210938

7 January 2021

Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210938

7 January 2021

mTOR and cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210938

7 January 2021

Clinical applications of angiogenic growth factors and their inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210938

7 January 2021

AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210938

7 January 2021

Childhood tumors of the nervous system as disorders of normal development

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210938

7 January 2021

The Akt-mTOR tango and its relevance to cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210938

7 January 2021

Exploiting the PI3K/AKT pathway for cancer drug discovery

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210938

7 January 2021

Proliferation of human neuroblastomas mediated by the epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210938

7 January 2021

Pterin-dependent tyrosine hydroxylase mRNA is not expressed in human melanocytes or melanoma cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210938

7 January 2021

Hedgehog and PI-3 kinase signaling converge on Nmyc1 to promote cell cycle progression in cerebellar neuronal precursors.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210938

7 January 2021

Insulin-like growth factor-I signaling in human neuroblastoma cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210938

7 January 2021

Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210938

7 January 2021

ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210938

7 January 2021

Regulation of cell size in growth, development and human disease: PI3K, PKB and S6K.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210938

7 January 2021

Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210938

7 January 2021

Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210938

7 January 2021

Evidence that cyclin D1 mediates both growth and proliferation downstream of TOR in hepatocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210938

7 January 2021

Activation of Akt predicts poor outcome in neuroblastoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210938

7 January 2021

The synthetic retinoid RO 13-6307 induces neuroblastoma differentiation in vitro and inhibits neuroblastoma tumour growth in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210938

7 January 2021

Celecoxib prevents neuroblastoma tumor development and potentiates the effect of chemotherapeutic drugs in vitro and in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210938

7 January 2021

Neuroblastoma: biology and molecular and chromosomal pathology

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210938

7 January 2021

The anti-VEGF antibody bevacizumab potently reduces the growth rate of high-risk neuroblastoma xenografts

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210938

7 January 2021

Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210938

7 January 2021

Synthesis and function of 3-phosphorylated inositol lipids

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210938

7 January 2021

c-Kit is preferentially expressed in MYCN-amplified neuroblastoma and its effect on cell proliferation is inhibited in vitro by STI-571.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210938

7 January 2021

Activation of the IGF-IR system contributes to malignant growth of human and mouse medulloblastomas.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210938

7 January 2021

Targeted expression of MYCN causes neuroblastoma in transgenic mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210938

7 January 2021

Disruption of cooperation between Ras and MycN in human neuroblastoma cells promotes growth arrest

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210938

7 January 2021

Ras and Myc can drive oncogenic cell proliferation through individual D-cyclins.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210938

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1210938

1 reference

Dimensions Publication ID

16 September 2017

0 references

1 reference